

**Table S1. Antibodies Used in This Study.** Primary and secondary antibodies used for immunoblots (IB) and immunofluorescence (IF).

| <b>Antibody</b>                         | <b>Host Species</b> | <b>Dilution</b> | <b>Vendor, Product #</b>            |
|-----------------------------------------|---------------------|-----------------|-------------------------------------|
| ITSN1                                   | Rabbit              | IB: 1:2500      | Novus Biologicals, NBP1-87806       |
| CLTA                                    | Rabbit              | 1:2500          | Novus Biologicals, NBP2-38638       |
| DNM2                                    | Rabbit              | 1:1000          | Novus Biologicals, NBP2-47477       |
| PICALM                                  | Rabbit              | 1:1000          | Atlas Antibodies, HPA019053         |
| FCHO1                                   | Rabbit              | 1:200           | Invitrogen, PA5-31603               |
| AP2A1                                   | Goat                | 1:16000         | LSBio, LS-B9566                     |
| Alpha tubulin                           | Rat                 | 1:500           | Thermo Fisher Scientific, MA1-80017 |
| MAP2                                    | Chicken             | 1:10000         | Thermo Fisher Scientific, PA1-10005 |
| Alexa Fluor 488 Goat anti-Rabbit IgG    | Goat                | 1:500           | Thermo Fisher Scientific, A11008    |
| Alexa Fluor 647 Goat anti-Rat IgG       | Goat                | 1:1000          | Thermo Fisher Scientific, A21247    |
| Alexa Fluor 647 Donkey anti-Chicken IgY | Donkey              | 1:500           | Thermo Fisher Scientific, A78952    |
| Alexa Fluor 568 Donkey anti-Rabbit IgG  | Donkey              | 1:500           | Thermo Fisher Scientific, A10042    |
| IRDye 800CW Donkey anti-Rabbit          | Donkey              | 1:20000         | LI-COR Biosciences, 926-32213       |
| IRDye 680RD Donkey anti-Mouse           | Donkey              | 1:20000         | LI-COR Biosciences, 926-68072       |

**Table S2. Statistics for Frontal Cortex Immunoblot Results.** This table shows the 2-way ANOVA results for frontal cortex (FC) immunoblots. Statistically significant results are in bold and trends are italicized.

|                     | ITSN1-L: Total Protein |                 | 2-way ANOVA |                    |                | Post-Hoc tests                    |                 |
|---------------------|------------------------|-----------------|-------------|--------------------|----------------|-----------------------------------|-----------------|
| Frontal Cortex      | Group                  | Mean $\pm$ SD   |             | F(DFn, DFd)        | p-value        | Šídák's multiple comparisons test |                 |
| ITSN1-L<br>190 kDa  | Male CTL               | 50 $\pm$ 28     | Interaction | F (1, 40) = 0.792  | P=0.379        | Male CTL vs AD                    | <b>P=0.049</b>  |
|                     | Male AD                | 29 $\pm$ 20     | Sex         | F (1, 40) = 3.718  | <i>P=0.061</i> | Female CTL vs AD                  | P=0.493         |
|                     | Female CTL             | 32 $\pm$ 14     | Diagnosis   | F (1, 40) = 5.820  | <b>P=0.021</b> | CTL Male vs Female                | P=0.103         |
|                     | Female AD              | 22 $\pm$ 16     |             |                    |                | AD Male vs Female                 | P=0.716         |
| CLTCa               | Male CTL               | 1817 $\pm$ 79   | Interaction | F (1, 39) = 6.652  | <b>P=0.014</b> | Male CTL vs AD                    | <i>P=0.055</i>  |
|                     | Male AD                | 1046 $\pm$ 916  | Sex         | F (1, 39) = 9.223  | <b>P=0.004</b> | Female CTL vs AD                  | P=0.323         |
|                     | Female CTL             | 458 $\pm$ 370   | Diagnosis   | F (1, 39) = 0.368  | P=0.548        | CTL Male vs Female                | <b>P=0.0007</b> |
|                     | Female AD              | 935 $\pm$ 880   |             |                    |                | AD Male vs Female                 | P=0.935         |
| CLTCb               | Male CTL               | 1967 $\pm$ 552  | Interaction | F (1, 41) = 0.384  | P=0.539        | Male CTL vs AD                    | P=0.253         |
|                     | Male AD                | 1523 $\pm$ 809  | Sex         | F (1, 41) = 6.012  | <b>P=0.019</b> | Female CTL vs AD                  | P=0.753         |
|                     | Female CTL             | 1342 $\pm$ 689  | Diagnosis   | F (1, 41) = 2.439  | P=0.126        | CTL Male vs Female                | <i>P=0.066</i>  |
|                     | Female AD              | 1151 $\pm$ 673  |             |                    |                | AD Male vs Female                 | P=0.373         |
| PICALM<br>65-75 kDa | Male CTL               | 3409 $\pm$ 1491 | Interaction | F (1, 41) = 0.829  | P=0.368        | –                                 | –               |
|                     | Male AD                | 3543 $\pm$ 1113 | Sex         | F (1, 41) = 1.185  | P=0.283        |                                   |                 |
|                     | Female CTL             | 3330 $\pm$ 1654 | Diagnosis   | F (1, 41) = 0.372  | P=0.545        |                                   |                 |
|                     | Female AD              | 2652 $\pm$ 1596 |             |                    |                |                                   |                 |
| PICALM<br>50 kDa    | Male CTL               | 242 $\pm$ 53    | Interaction | F (1, 39) = 2.589  | P=0.116        | –                                 | –               |
|                     | Male AD                | 430 $\pm$ 235   | Sex         | F (1, 39) = 0.0002 | P=0.989        |                                   |                 |
|                     | Female CTL             | 341 $\pm$ 147   | Diagnosis   | F (1, 39) = 2.232  | P=0.143        |                                   |                 |
|                     | Female AD              | 334 $\pm$ 270   |             |                    |                |                                   |                 |
| AP2A1               | Male CTL               | 58 $\pm$ 25     | Interaction | F (1, 40) = 2.487  | P=0.123        | –                                 | –               |
|                     | Male AD                | 59 $\pm$ 18     | Sex         | F (1, 40) = 0.182  | P=0.672        |                                   |                 |
|                     | Female CTL             | 70 $\pm$ 14     | Diagnosis   | F (1, 40) = 1.920  | P=0.174        |                                   |                 |
|                     | Female AD              | 51 $\pm$ 24     |             |                    |                |                                   |                 |
| FCHO1               | Male CTL               | 52 $\pm$ 21     | Interaction | F (1, 40) = 0.010  | P=0.922        | –                                 | –               |
|                     | Male AD                | 44 $\pm$ 14     | Sex         | F (1, 40) = 1.384  | P=0.246        |                                   |                 |
|                     | Female CTL             | 46 $\pm$ 20     | Diagnosis   | F (1, 40) = 2.165  | P=0.149        |                                   |                 |
|                     | Female AD              | 37 $\pm$ 16     |             |                    |                |                                   |                 |
| DNM2                | Male CTL               | 295 $\pm$ 174   | Interaction | F (1, 41) = 0.0637 | P=0.802        | –                                 | –               |
|                     | Male AD                | 286 $\pm$ 124   | Sex         | F (1, 41) = 0.0890 | P=0.767        |                                   |                 |
|                     | Female CTL             | 293 $\pm$ 118   | Diagnosis   | F (1, 41) = 0.222  | P=0.640        |                                   |                 |
|                     | Female AD              | 263 $\pm$ 122   |             |                    |                |                                   |                 |


**Table S3. Statistics for Hippocampus Immunoblot Results.** This table shows the 2-way ANOVA results for hippocampal immunoblots. Statistically significant results are in bold and trends are italicized.

|                     | ITSN1-L: Total Protein |            | 2-way ANOVA |                    |                | Post-Hoc tests                  |                |
|---------------------|------------------------|------------|-------------|--------------------|----------------|---------------------------------|----------------|
| Hippocampus         | Group                  | Mean ± SD  |             | F(DFn, DFd)        | p-value        | Šídák multiple comparisons test |                |
| ITSN1-L<br>190 kDa  | Male CTL               | 13 ± 12    | Interaction | F (1, 52) = 6.45   | <b>P=0.014</b> | Male CTL vs AD                  | P=0.459        |
|                     | Male AD                | 23 ± 16    | Sex         | F (1, 52) = 9.372  | <b>P=0.004</b> | Female CTL vs AD                | <b>P=0.034</b> |
|                     | Female CTL             | 49 ± 43    | Diagnosis   | F (1, 52) = 0.890  | P=0.287        | CTL Male vs Female              | <b>P=0.001</b> |
|                     | Female AD              | 26 ± 18    |             |                    |                | AD Male vs Female               | P=0.897        |
| ITSN1-S<br>130 kDa  | Male CTL               | 40 ± 33    | Interaction | F (1, 52) = 0.025  | P=0.875        | Male CTL vs AD                  | <i>P=0.053</i> |
|                     | Male AD                | 80 ± 50    | Sex         | F (1, 52) = 0.104  | P=0.749        | Female CTL vs AD                | <b>P=0.031</b> |
|                     | Female CTL             | 41 ± 31    | Diagnosis   | F (1, 52) = 11.420 | <b>P=0.001</b> | CTL Male vs Female              | P=0.993        |
|                     | Female AD              | 86 ± 56    |             |                    |                | AD Male vs Female               | P=0.912        |
| CLTCa               | Male CTL               | 279 ± 187  | Interaction | F (1, 49) = 0.001  | P=0.972        | –                               | –              |
|                     | Male AD                | 332 ± 152  | Sex         | F (1, 49) = 0.505  | P=0.481        |                                 |                |
|                     | Female CTL             | 316 ± 151  | Diagnosis   | F (1, 49) = 1.025  | P=0.316        |                                 |                |
|                     | Female AD              | 366 ± 202  |             |                    |                |                                 |                |
| CLTCb               | Male CTL               | 289 ± 115  | Interaction | F (1, 51) = 0.874  | P=0.354        | –                               | –              |
|                     | Male AD                | 358 ± 107  | Sex         | F (1, 51) = 3.429  | P=0.070        |                                 |                |
|                     | Female CTL             | 422 ± 257  | Diagnosis   | F (1, 51) = 0.253  | P=0.617        |                                 |                |
|                     | Female AD              | 401 ± 186  |             |                    |                |                                 |                |
| PICALM<br>65-75 kDa | Male CTL               | 980 ± 543  | Interaction | F (1, 52) = 1.825  | P=0.183        | –                               | –              |
|                     | Male AD                | 1097 ± 427 | Sex         | F (1, 52) = 1.517  | P=0.224        |                                 |                |
|                     | Female CTL             | 1292 ± 378 | Diagnosis   | F (1, 52) = 0.1412 | P=0.709        |                                 |                |
|                     | Female AD              | 1083 ± 433 |             |                    |                |                                 |                |
| PICALM<br>50 kDa    | Male CTL               | 172 ± 96   | Interaction | F (1, 52) = 3.981  | <i>P=0.051</i> | –                               | –              |
|                     | Male AD                | 208 ± 72   | Sex         | F (1, 52) = 1.496  | P=0.227        |                                 |                |
|                     | Female CTL             | 265 ± 159  | Diagnosis   | F (1, 52) = 0.553  | P=0.461        |                                 |                |
|                     | Female AD              | 186 ± 94   |             |                    |                |                                 |                |
| AP2A1               | Male CTL               | 42 ± 33    | Interaction | F (1, 51) = 0.619  | P=0.435        | –                               | –              |
|                     | Male AD                | 49 ± 15    | Sex         | F (1, 51) = 1.999  | P=0.163        |                                 |                |
|                     | Female CTL             | 55 ± 26    | Diagnosis   | F (1, 51) = 0.112  | P=0.740        |                                 |                |
|                     | Female AD              | 52 ± 14    |             |                    |                |                                 |                |
| FCHO1               | Male CTL               | 93 ± 37    | Interaction | F (1, 50) = 0.0853 | P=0.772        | –                               | –              |
|                     | Male AD                | 83 ± 40    | Sex         | F (1, 50) = 0.0219 | P=0.883        |                                 |                |
|                     | Female CTL             | 98 ± 49    | Diagnosis   | F (1, 50) = 1.487  | P=0.229        |                                 |                |
|                     | Female AD              | 81 ± 36    |             |                    |                |                                 |                |
| DNM2                | Male CTL               | 53 ± 21    | Interaction | F (1, 51) = 1.042  | P=0.312        | –                               | –              |
|                     | Male AD                | 80 ± 33    | Sex         | F (1, 51) = 3.517  | <i>P=0.066</i> |                                 |                |
|                     | Female CTL             | 79 ± 45    | Diagnosis   | F (1, 51) = 3.817  | <i>P=0.056</i> |                                 |                |
|                     | Female AD              | 87 ± 28    |             |                    |                |                                 |                |

**Table S4. Statistics for Cortical and Hippocampal ITSN1 Immunoblot Results.** This table shows the 2-way ANOVA results for hippocampal and cortex immunoblots of ITSN1-L in 5xFAD and WT mice over time. Statistically significant results are in bold and trends italicized.


|             | ITSN1-L : Total Protein |           | 2-way ANOVA results |                    |                 | Post-Hoc tests                  |                 |
|-------------|-------------------------|-----------|---------------------|--------------------|-----------------|---------------------------------|-----------------|
| Cortex      | Group                   | Mean ± SD |                     | F (DFn, DFd)       | P value         | Šídák multiple comparisons test |                 |
| 1 month     | Male WT                 | 402 ± 33  | Interaction         | F (1, 23) = 0.299  | P=0.590         | –                               | –               |
|             | Male 5X                 | 412 ± 75  | Sex                 | F (1, 23) = 0.910  | P=0.350         |                                 |                 |
|             | Female WT               | 413 ± 78  | Genotype            | F (1, 23) = 0.846  | P=0.367         |                                 |                 |
|             | Female 5X               | 450 ± 70  |                     |                    |                 |                                 |                 |
| 3 months    | Male WT                 | 446 ± 68  | Interaction         | F (1, 19) = 0.909  | P=0.353         | Male WT vs 5X                   | P=0.324         |
|             | Male 5X                 | 507 ± 98  | Sex                 | F (1, 19) = 1.341  | P=0.261         | Female WT vs 5X                 | <b>P=0.031</b>  |
|             | Female WT               | 379 ± 51  | Genotype            | F (1, 19) = 8.320  | <b>P=0.0095</b> | WT Male vs Female               | P=0.265         |
|             | Female 5X               | 501 ± 78  |                     |                    |                 | 5X Male vs Female               | P=0.988         |
| 6 months    | Male WT                 | 460 ± 112 | Interaction         | F (1, 22) = 3.550  | P=0.0728        | Male WT vs 5X                   | P=0.911         |
|             | Male 5X                 | 440 ± 112 | Sex                 | F (1, 22) = 0.3573 | P=0.5561        | Female WT vs 5X                 | <b>P=0.011</b>  |
|             | Female WT               | 548 ± 44  | Genotype            | F (1, 22) = 5.958  | <b>P=0.023</b>  | WT Male vs Female               | P=0.200         |
|             | Female 5X               | 394 ± 71  |                     |                    |                 | 5X Male vs Female               | P=0.582         |
| 9 months    | Male WT                 | 844 ± 85  | Interaction         | F (1, 22) = 0.668  | P=0.423         | Male WT vs 5X                   | <b>P=0.001</b>  |
|             | Male 5X                 | 525 ± 191 | Sex                 | F (1, 22) = 0.080  | P=0.780         | Female WT vs 5X                 | <b>P=0.040</b>  |
|             | Female WT               | 771 ± 139 | Genotype            | F (1, 22) = 16.00  | <b>P=0.0006</b> | WT Male vs Female               | P=0.722         |
|             | Female 5X               | 561 ± 185 |                     |                    |                 | 5X Male vs Female               | P=0.903         |
| Hippocampus |                         |           |                     |                    |                 |                                 |                 |
| 1 month     | Male WT                 | 281 ± 49  | Interaction         | F (1, 21) = 0.326  | P=0.574         | –                               | –               |
|             | Male 5X                 | 292 ± 54  | Sex                 | F (1, 21) = 0.006  | P=0.937         |                                 |                 |
|             | Female WT               | 272 ± 34  | Genotype            | F (1, 21) = 1.339  | P=0.2603        |                                 |                 |
|             | Female 5X               | 304 ± 14  |                     |                    |                 |                                 |                 |
| 3 months    | Male WT                 | 621 ± 96  | Interaction         | F (1, 18) = 1.053  | P=0.318         | –                               | –               |
|             | Male 5X                 | 601 ± 27  | Sex                 | F (1, 18) = 1.217  | P=0.285         |                                 |                 |
|             | Female WT               | 564 ± 58  | Genotype            | F (1, 18) = 0.080  | P=0.781         |                                 |                 |
|             | Female 5X               | 599 ± 32  |                     |                    |                 |                                 |                 |
| 6 months    | Male WT                 | 407 ± 59  | Interaction         | F (1, 22) = 4.901  | <b>P=0.038</b>  | Male WT vs 5X                   | <b>P=0.0002</b> |
|             | Male 5X                 | 287 ± 40  | Sex                 | F (1, 22) = 1.368  | P=0.255         | Female WT vs 5X                 | P=0.222         |
|             | Female WT               | 346 ± 25  | Genotype            | F (1, 22) = 20.13  | <b>P=0.0002</b> | WT Male vs Female               | <i>P=0.061</i>  |
|             | Female 5X               | 305 ± 54  |                     |                    |                 | 5X Male vs Female               | P=0.697         |
| 9 months    | Male WT                 | 406 ± 118 | Interaction         | F (1, 22) = 1.401  | P=0.249         | Male WT vs 5X                   | P=0.286         |
|             | Male 5X                 | 313 ± 35  | Sex                 | F (1, 22) = 4.702  | <b>P=0.041</b>  | Female WT vs 5X                 | <b>P=0.004</b>  |
|             | Female WT               | 547 ± 129 | Genotype            | F (1, 22) = 11.71  | <b>P=0.0024</b> | WT Male vs Female               | <i>P=0.057</i>  |
|             | Female 5X               | 354 ± 103 |                     |                    |                 | 5X Male vs Female               | P=0.738         |

## Frontal Cortex




**Figure S1. Other CME Proteins Are Not Changed in AD Frontal Cortex.** Comparison of proteins involved in CME between males and females in AD and CTL frontal cortex (FC). Proteins examined include PICALM isoforms 1,2 (A) and isoform 4 (B), FCHO1 (C), AP2A1 (D), and DNM2 (E). For each analysis, all graphs show protein intensity values normalized to total protein stain (TPS) with representative immunoblot bands underneath. Data are represented as mean  $\pm$  SEM. Statistical significance was determined by two-way ANOVA, with post-hoc Šídák multiple comparisons tests for analyses with significant group effects. \* $P < 0.05$


## Hippocampus



**Figure S2. Other CME Proteins Are Not Changed in AD Hippocampus.** Comparison of proteins involved in CME between males and females in AD and CTL hippocampus. Proteins examined include PICALM isoforms 1,2 (A) and isoform 4 (B), FCHO1 (C), AP2A1 (D), and DNM2 (E). For each analysis, all graphs show protein intensity values normalized to total protein stain (TPS) with representative immunoblot bands underneath. Data are represented as mean  $\pm$  SEM. Statistical significance was determined by two-way ANOVA, with post-hoc Šídák multiple comparisons tests for analyses with significant group effects. \* $P < 0.05$



**Figure S3. Clathrin Light Chain Shows No Change In AD but Reveals a Significant Sex Difference in CTLs.** Comparison of Clathrin Light Chain A (CLTA) and Clathrin Light Chain B (CLTB) between males and females in AD and CTL frontal cortex (FC) and hippocampus (HP). For each analysis, all graphs (A, B, C, D) show protein intensity values normalized to total protein stain (TPS) with representative immunoblot bands underneath. Data are represented as mean  $\pm$  SEM. Statistical significance was determined by two-way ANOVA, with post-hoc Šídák multiple comparisons tests for analyses with significant group effects. \* $P < 0.05$



**Figure S4. ITSN1 Expression Visualized in Female 9-month Wildtype and 5xFAD Mice.**

Representative wide field images of female 9 month old WT (A) and 5xFAD (B) mouse brains stained for ITSN1 (yellow). White boxes in indicate areas magnified in the cortex (B) and hippocampus (C) in WT, and the cortex (E) and hippocampus (F) in 5xFAD. Each region is shown with both ITSN1 (yellow) and DAPI (cyan). Scale bars are 500  $\mu\text{m}$  in A and D, and 50  $\mu\text{m}$  in C, D, and E.